Predict your next investment

Corporation
HEALTHCARE | Drug Development
inviragen.com

See what CB Insights has to offer

Executives

4

Board of Directors

1

Inviragen Board of Director

1 Board of directors

Inviragen has 1 board of directors, including Fred Schwarzer.

Name

Firm

Work History

Other Seats

Fred Schwarzer

Fred has extensive operational and fundraising experience, including the development of corporate partnerships and the structuring of venture capital investments and acquisitions.Prior to founding CLS, Fred was the chief executive officer and then chairman of Heska(HSKA). During his tenure at Heska, Fred completed corporate partnerships with Bayer and Novartis, completed seven acquisitions and Heska�s initial public offering and follow-on public offering. During this time, Heska also obtained its first FDA approval, launched its first products, created its sales and marketing effort and grew its revenue to approximately $40 million.Fred has also been the president and chief executive officer of Mingly Capital Corporation,which was focused on developing cross-border opportunities in life sciences and information technology. He was also executive director of the Mingly Corporation Limited(listed on the Hong Kong Stock Exchange) and prior to that he was a senior vice president of C.M. Capital,a diversified asset management company.Fred began his professional career as an attorney representing technology companies and venture capitalists. In 1985, he was made a partner with Pillsbury, Madison & Sutro (now Pillsbury, Winthrop) and in 1988 he founded the firm of General Counsel Associates (now GCA Law Partners).Fred holds a JD from the University of California, Berkeley, Boalt Hall School of Law and a BA from the University of Michigan.

Amaranth Medical, APT Pharmaceuticals, Kereos, Minimally Invasive Devices, and Visioneering Technologies

Name

Fred Schwarzer

Firm

Work History

Fred has extensive operational and fundraising experience, including the development of corporate partnerships and the structuring of venture capital investments and acquisitions.Prior to founding CLS, Fred was the chief executive officer and then chairman of Heska(HSKA). During his tenure at Heska, Fred completed corporate partnerships with Bayer and Novartis, completed seven acquisitions and Heska�s initial public offering and follow-on public offering. During this time, Heska also obtained its first FDA approval, launched its first products, created its sales and marketing effort and grew its revenue to approximately $40 million.Fred has also been the president and chief executive officer of Mingly Capital Corporation,which was focused on developing cross-border opportunities in life sciences and information technology. He was also executive director of the Mingly Corporation Limited(listed on the Hong Kong Stock Exchange) and prior to that he was a senior vice president of C.M. Capital,a diversified asset management company.Fred began his professional career as an attorney representing technology companies and venture capitalists. In 1985, he was made a partner with Pillsbury, Madison & Sutro (now Pillsbury, Winthrop) and in 1988 he founded the firm of General Counsel Associates (now GCA Law Partners).Fred holds a JD from the University of California, Berkeley, Boalt Hall School of Law and a BA from the University of Michigan.

Other Seats

Amaranth Medical, APT Pharmaceuticals, Kereos, Minimally Invasive Devices, and Visioneering Technologies

Inviragen Management Team

4 Team Members

Inviragen has 4 executives. Inviragen's current Chief Executive Officer is Dan Stinchcomb.

Name

Work History

Title

Status

Dan Stinchcomb

Chief Executive Officer

Current

Joseph Santangelo

Chief Operating Officer

Current

Jorge Osorio

Chief Security Officer

Current

Gilad S Gordon

Chief Medical Officer

Current

Name

Dan Stinchcomb

Joseph Santangelo

Jorge Osorio

Gilad S Gordon

Work History

Title

Chief Executive Officer

Chief Operating Officer

Chief Security Officer

Chief Medical Officer

Status

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.